用癌症通路模型优化生成分子设计,提升抗癌药物发现效率
Pathway-Guided Optimization of Deep Generative Molecular Design Models for Cancer Therapy
- 将通路动力学模型嵌入生成模型潜空间,指导分子优化
- 通过模拟药物对癌通路的调控,筛选更有效候选分子
- 适合药物研发人员及生成模型研究者参考
基于数据的药物设计可被建模为在庞大高维且结构化的分子空间中优化一个昂贵的黑箱目标函数。连接树变分自编码器(JTVAE)已被证明是一种高效的生成模型,可用于生成具有优良性质的新颖类药物小分子。尽管生成分子设计(GMD)方案的性能强烈依赖于初始训练数据,但通过优化潜空间可显著提升其采样效率,从而发现性质更优的分子。本文提出利用机制模型(如由微分方程描述的通路模型)对JTVAE等GMD模型进行潜空间优化(LSO)。为验证该方法潜力,我们展示了如何将药效动力学模型——通过预测小分子如何调控癌症通路来评估其治疗效果——整合进数据驱动模型的潜空间优化中,实现更有效的分子生成。
原文摘要 · Abstract (English)
The data-driven drug design problem can be formulated as an optimization task of a potentially expensive black-box objective function over a huge high-dimensional and structured molecular space. The junction tree variational autoencoder (JTVAE) has been shown to be an efficient generative model that can be used for suggesting legitimate novel drug-like small molecules with improved properties. While the performance of the generative molecular design (GMD) scheme strongly depends on the initial training data, one can improve its sampling efficiency for suggesting better molecules with enhanced properties by optimizing the latent space. In this work, we propose how mechanistic models - such as pathway models described by differential equations - can be used for effective latent space optimization(LSO) of JTVAEs and other similar models for GMD. To demonstrate the potential of our proposed approach, we show how a pharmacodynamic model, assessing the therapeutic efficacy of a drug-like small molecule by predicting how it modulates a cancer pathway, can be incorporated for effective LSO of data-driven models for GMD.
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。